Servicio Navarro de Salud - Osasunbidea, Pamplona, Spain.
Eur J Hosp Pharm. 2020 Jan;27(1):49-51. doi: 10.1136/ejhpharm-2018-001669. Epub 2018 Sep 25.
A possible case of sprue-like enteropathy (SLE) induced by the use of telmisartan is reported. Telmisartan is an angiotensin-receptor II blocker (type 1) used for the treatment of hypertension. Several cases of SLE associated with olmesartan and other drugs of the same group have been reported. In all cases, SLE resolved following therapy withdrawal. We describe the case of an 80-year-old woman who presented with diarrhoea and abdominal pain. In the past 5 years she had been treated with telmisartan 40 mg once a day for hypertension, so we hypothesised that symptoms might be caused by telmisartan. After treatment discontinuation, diarrhoea disappeared. Three causality algorithms were applied and revealed a possible or likely causal relationship. At present, the patient remains asymptomatic. There is a causal relationship between the use of telmisartan and SLE. This association should be taken into account by physicians when prescribing and reviewing drug therapies.
报告了一例可能由替米沙坦引起的类似口炎性腹泻病（SLE）。替米沙坦是一种血管紧张素受体 II 阻滞剂（1 型），用于治疗高血压。已经有几例与奥美沙坦和同组其他药物相关的 SLE 病例报告。在所有情况下，停用 SLE 治疗后均得到缓解。我们描述了一位 80 岁女性的病例，她出现腹泻和腹痛。在过去 5 年中，她每天服用替米沙坦 40mg 治疗高血压，因此我们假设症状可能是由替米沙坦引起的。停用治疗后，腹泻消失了。应用了三种因果关系算法，结果表明存在可能或很可能的因果关系。目前，患者无症状。替米沙坦的使用与 SLE 之间存在因果关系。医生在开具和审查药物治疗方案时应考虑到这种关联。
